Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso-García, Miriam, Sánchez-Gastaldo, Amparo, Muñoz-Fuentes, Miguel A., Molina-Pinelo, Sonia, Boyero, Laura, Benedetti, Johana Cristina, Bernabé-Caro, Reyes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147485/
https://www.ncbi.nlm.nih.gov/pubmed/35631359
http://dx.doi.org/10.3390/ph15050533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147485/
https://www.ncbi.nlm.nih.gov/pubmed/35631359
http://dx.doi.org/10.3390/ph15050533

Ejemplares similares